Company research
HARROW, INC.
CIK 1360214Updated Sep 26, 2026
SecurityHROW · NASDAQ · equity
Name history
HARROW HEALTH, INC. · through Sep 20, 2023Imprimis Pharmaceuticals, Inc. · through Dec 17, 2018TRANSDEL PHARMACEUTICALS INC · through Feb 27, 2012Bywater Resources, Inc · through Sep 12, 2007
HROW price & chart
Loading TradingView…
NASDAQ:HROW on TradingView ↗In the news
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare ↗
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals News provided by Formosa Pharmaceuticals Inc. Jun 09, 2025, 07:00 ET Share this article Share to X Share this article Share to X TAIPEI , June 9, 2025 /PRNewswire/ -- H ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
SCHEDULE 13G/A filing
Show 5 more recent filings
4 filing
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 399,482,000Source | 388,971,000Source | 312,164,000Source | 157,378,000Source |
| Property, Plant and Equipment, NetUSD | 3,260,000Source | 3,734,000Source | 3,521,000Source | 3,486,000Source |
| GoodwillUSD | 332,000Source | 332,000Source | 332,000Source | 332,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 175,174,000Source | 184,949,000Source | 159,906,000Source | 23,725,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 72,927,000Source | 47,247,000Source | 74,085,000Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 110,895,000Source | 116,373,000Source | 36,261,000Source | 6,249,000Source |
| Inventory, NetUSD | 13,523,000Source | 10,702,000Source | 10,867,000Source | 6,541,000Source |
| Assets, CurrentUSD | 211,750,000Source | 189,651,000Source | 139,482,000Source | 118,260,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,405,000Source | 15,329,000Source | 9,588,000Source | 3,611,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,783,000Source | 8,554,000Source | 6,785,000Source | 7,513,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 347,391,000Source | 319,674,000Source | 241,753,000Source | 130,138,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 37,000Source | 35,000Source | 35,000Source | 30,000Source |
| Additional Paid in CapitalUSD | 208,933,000Source | 221,002,000Source | 204,635,000Source | 137,058,000Source |
| Retained Earnings (Accumulated Deficit)USD | -156,524,000Source | -151,385,000Source | -133,904,000Source | -109,493,000Source |
| Stockholders' Equity Attributable to ParentUSD | 52,446,000Source | 69,652,000Source | 70,766,000Source | 27,595,000Source |
| Liabilities and EquityUSD | 399,482,000Source | 388,971,000Source | 312,164,000Source | 157,378,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 96,302,000Source | 91,343,000Source | 49,344,000Source | 18,632,000Source |
| Operating Lease, Liability, CurrentUSD | 887,000Source | 497,000Source | 806,000Source | 723,000Source |
| Accounts Payable, CurrentUSD | 35,355,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 7,905,000Source | 8,792,000Source | 6,524,000Source | 7,332,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -355,000Source | -355,000Source | -355,000Source | -355,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 20,147,000Source | 15,146,000Source | 779,000Source |
| Long-term DebtUSD | 250,000,000Source | 262,737,000Source | 246,717,000Source | 151,773,000Source |
| Short-term InvestmentsUSD | — | — | 8,681,000Source | 5,589,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,502,000Source | 17,619,000Source | 15,696,000Source | 7,974,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -5,010,000Source | 80,232,000Source | 30,344,000Source | 1,860,000Source |
| Increase (Decrease) in InventoriesUSD | 2,821,000Source | -165,000Source | 4,326,000Source | 2,324,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 43,864,000Source | -22,202,000Source | 3,840,000Source | 1,705,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,460,000Source | -33,164,000Source | -152,553,000Source | -1,743,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 887,000Source | 1,595,000Source | 1,460,000Source | 2,597,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -12,724,000Source | 28,528,000Source | 126,528,000Source | 54,141,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 25,680,000Source | -26,838,000Source | -22,185,000Source | 54,103,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 96,270,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 18,718,000Source | 20,594,000Source | 18,887,000Source | 6,480,000Source |
| Income Taxes Paid, NetUSD | 93,000Source | 374,000Source | — | 75,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,502,000Source | 17,619,000Source | 15,696,000Source | 7,974,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 4,050,000Source | 4,205,000Source | 4,097,000Source | 782,000Source |
| Amortization of Intangible AssetsUSD | 16,991,000Source | 11,783,000Source | 10,082,000Source | 1,578,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | 4,358,000Source | — | — | — |
| Depreciation, Amortization and Accretion, NetUSD | 1,315,000Source | 1,269,000Source | 1,055,000Source | 1,253,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 168,000Source | 99,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | -253,000Source | — | 686,000Source |
| Gain (Loss) on InvestmentsUSD | — | -3,171,000Source | 3,092,000Source | -2,914,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -13,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -7,750,000Source | — | — | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | 5,259,000Source |
| GoodwillUSD | 332,000Source | 332,000Source | 332,000Source | 332,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | — | 380,000Source | — |
| Income Tax Expense (Benefit)USD | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| InterestExpenseNonoperatingUSD | 24,180,000Source | 22,786,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,139,000Source | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Nonoperating Income (Expense)USD | -31,883,000Source | -26,142,000Source | -24,141,000Source | -15,930,000Source |
| Operating ExpensesUSD | 173,854,000Source | 141,547,000Source | 90,122,000Source | 61,293,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,232,000Source | 1,117,000Source |
| Other Nonoperating Income (Expense)USD | 47,000Source | -185,000Source | -444,000Source | 102,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 22,655,000Source |
| Proceeds from Stock Options ExercisedUSD | 467,000Source | 1,110,000Source | 379,000Source | 642,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 272,303,000Source | 199,614,000Source | 130,193,000Source | 88,595,000Source |
| Cost of RevenueUSD | 67,934,000Source | 49,245,000Source | 39,640,000Source | 25,383,000Source |
| Selling, General and Administrative ExpenseUSD | 152,914,000Source | 129,064,000Source | 83,090,000Source | 58,243,000Source |
| Operating Income (Loss)USD | 30,515,000Source | 8,822,000Source | 431,000Source | 1,919,000Source |
| Other Nonoperating Income (Expense)USD | 47,000Source | -185,000Source | -444,000Source | 102,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,368,000Source | -17,320,000Source | -23,710,000Source | -14,011,000Source |
| Income Tax Expense (Benefit)USD | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| Net Income (Loss) Attributable to ParentUSD | -5,139,000Source | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Earnings Per Share, BasicUSD per share | -0.14Source | -0.49Source | -0.75Source | -0.51Source |
| Earnings Per Share, DilutedUSD per share | -0.14Source | -0.49Source | -0.75Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 36,760,461Source | 35,650,714Source | 32,616,777Source | 27,460,968Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 36,760,461Source | 35,650,714Source | 32,616,777Source | — |
| Interest Expense (non-operating)USD | 24,180,000Source | 22,786,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 16,991,000Source | 11,783,000Source | 10,082,000Source | 1,578,000Source |
| Current Income Tax Expense (Benefit)USD | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,915,000Source | 1,850,000Source | 1,530,000Source | 1,477,000Source |
| Gain (Loss) on InvestmentsUSD | — | -3,171,000Source | 3,092,000Source | -2,914,000Source |
| Gross ProfitUSD | 204,369,000Source | 150,369,000Source | 90,553,000Source | 63,212,000Source |
| Interest ExpenseUSD | — | — | 21,324,000Source | 7,244,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Nonoperating Income (Expense)USD | -31,883,000Source | -26,142,000Source | -24,141,000Source | -15,930,000Source |
| Operating ExpensesUSD | 173,854,000Source | 141,547,000Source | 90,122,000Source | 61,293,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,232,000Source | 1,117,000Source |
| Research and Development ExpenseUSD | 20,940,000Source | 12,230,000Source | 6,652,000Source | 3,050,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure) VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially …
Read attachment ↗ex99-2.htm · 8-K · 2026-08-10
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules; the second half is about converting growing demand into revenue and profits. The balance of this Letter to Stockholders describes why I believe we are set up well - for not only the second half of 2026, but for many years to come, including the opportunity to achieve our ambitious company-…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease NASHVILLE, Tenn., August 6, 2026 - Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonis…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Harrow Announces First Quarter 2026 Financial Results First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) ────────────────────────────────────────────────────────────────────────────────────────────────────── VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $4…
Read attachment ↗ex99-2.htm · 8-K · 2026-05-11
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 26th Quarterly Letter to Stockholders May 11, 2026 Dear Harrow Stockholders: The first quarter of 2026 saw unprecedented market demand for VEVYE ® and an unavoidable modeling challenge related to our new commercial coverage. While we were pleased with the former (the unprecedented demand for VEVYE), the latter resulted in a non-recurring revenue reduction for the quarter. That said, the underlying fundamentals of Harrow have never been stronger. …
Read attachment ↗